Home> Work Package 7: Dissemination and Communication

Work Package 7: Dissemination and Communication

WP7 plays a pivotal role in the entire project. For HARMONY to succeed, it is critical that the data and information gathered is disseminated and shared widely. The free flow of information through multi-layered communication channels will engage key stakeholders.

Objectives

Developing an awareness among the different groups within this Network of Excellence of the progress that is being made and of the outcomes that have been achieved;
Facilitating the planning and dissemination of all activities, thus aligning content and results;
Monitoring, evaluating, and communicating the quality and impact of the dissemination of information;
Raising awareness of HARMONY’s work in a coherent, consistent, and sensitive manner;
Build and maintain the HARMONY community;
Ensuring that communications can be read not only by professionals, but also by a broader audience.

Work Package Partners

AEMPS, Amgen, AP-HP, Barts Health, Bayer, BFArM, Celgene, EAPM, EBMT, EHA, ELN, EORTC, Erasmus MC, ERIC, FISM Onlus, GFM, GMV, Goethe University, GPOH, GRAALL, GRL-SANGER, HHU, HULAFE, IBSAL, IJC, Janssen, LeukaNet, LMU, LYSA, MediSapiens, MediUni Wien, Menarini, MLL, MU, Newcastle University, NICE, Novartis, OPBG, Synapse, Takeda, Ulm University, UNIBO, UNITO, University of Cambridge, University of Helsinki, University of Navarra, University of Rome Tor Vergata, University of York, VHIO, VIB, Vumc.

Relevant links:

Manifesto - June 2023: Call to leverage big data to accelerate blood cancer research | About the HARMONY Alliance >
Become involved - June 2023: Co-operative working groups, hospitals and academic institutions are invited to collaborate >
General introduction: HARMONY Alliance - PPT: June 2023 >
General introduction: HARMONY Alliance Foundation - PPT: June 2023 >
White paper - June 2019: Big Data to enable better and faster treatment for Patients with Blood Cancer >
Policy strategy - December 2018: Policy Strategy for European, National and Regional Decision-Makers in Europe >

Work Package Leadership

Public-private partnership for Big Data in Hematology

HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).